Combination therapy comprising anti-IL-23 antibody and corticosteroid for treatment of psoriasis
Through the combination of IL-23 antagonist and corticosteroids, the problem of insufficient response in the treatment of plaque psoriasis was solved, which significantly improved the significance and durability of the treatment response, and achieved more Good therapeutic effect.
Patent Information
- Application Number
- CN202380025268.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-13
- Filing Date
- 2023-01-12
- Publication Date
- 2024-12-06
AI Technical Summary
Current IL-23 inhibitor therapy In the treatment of plaque psoriasis, about half of patients failed to achieve a treatment response of ≤3% of body surface area (BSA) at week 16, and response tolerance and durability insufficient.
Combined with IL-23 antagonist and corticosteroids, the response maintenance was continued by applying corticosteroids to BSA >3% of patients twice daily at week 16 for 4 weeks, and then stopping corticosteroid treatment.
Significantly increased the percentage of BSA, PGA, PGA x BSA and DLQI reduction, the response improved significantly at week 20, and the response remained at week 24 after stopping corticosteroid therapy, improving the tolerance and durability of the treatment .
Smart Images

Figure HDA0005024845340000011 
Figure HDA0005024845340000012 
Figure HDA0005024845340000021
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 299,181, filed on January 13, 2022, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present invention provides a combination therapy comprising an IL-23 antagonist and a corticosteroid. The combination therapy of the present invention can be used to treat, prevent or alleviate plaque psoriasis. Supplementing IL-23 inhibitor therapy with a corticosteroid will enhance the anti-psoriatic therapeutic effect of the IL-23 inhibitor. Background Art
[0004] Psoriasis is a chronic inflammatory skin disease that affects approximately 3% of adults in the United States (JAMADermatol.2021;157(8):940-946). It is characterized by significant inflammation and increased epidermal thickness, which is caused by infiltration of activated T cells into the skin and abnormal proliferation and differentiation of keratinocytes. Moderate to severe psoriasis is associated with many comorbidities, including metabolic syndrome, cardiovascular and cerebrovascular diseases, depression, and anxiety (Acad Dermatol.2017;76(3):377-390). Patients may also experience mental health problems and reduced quality of life (Patient Relat Outcome Meas.2015;6167-177).
[0005] Treatment options include topical therapy and phototherapy for localized psoriasis, systemic medications and biologics for generalized psoriasis (J Am Acad Dermatol. 2008; 58(5): 826-850). For plaque psoriasis, the National Psoriasis Foundation recommends that an acceptable response is an affected body surface area (BSA) ≤ 3% and a target response is BSA ≤ 1% after 3 months of treatment (J Am Acad Dermatol. 2017; 76(2): 290-298).
[0006] Drugs that inhibit TNF-a have been approved for the treatment of psoriasis, including the biologic infliximab Adalimumab Etanercept Infliximab and adalimumab are chimeric and fully human antibodies, respectively, that bind to human TNF-a. Etanercept is a fusion protein consisting of the extracellular region of the human p75 TNF receptor fused to the Fc portion of an antibody and is currently used as a systemic treatment for moderate to severe plaque psoriasis.
[0007] Among biologics, tildrakizumab is a humanized IgG1 monoclonal antibody that selectively binds to interleukin-23 (IL-23) and inhibits its receptor interaction. Randomized, controlled trials have shown that tildrakizumab monotherapy is effective for the treatment of psoriasis and is well tolerated compared with placebo in patients with chronic moderate to severe plaque psoriasis. However, in a cohort study, almost half of the patients did not achieve a BSA 3% at week 16 using tildrakizumab.
[0008] Surprisingly, the inventors have found that adjunctive use of topical halcinonide ointment for 4 weeks effectively improved all outcomes in these patients, as reflected in decreases in mean BSA, PGA, and BSA x PGA from week 16 to week 20, and an increase in the proportion of all patients with BSA ≤ 3%. Furthermore, the enhanced response was maintained through week 24 after cessation of supplemental halcinonide ointment for 4 weeks. Furthermore, the inventors have found that a patient's response to teikizumab can be enhanced by supplemental halcinonide ointment without the need to increase the teikizumab dose or switch to a new biologic. Summary of the invention
[0009] Therefore, the present invention provides a combination therapy comprising an IL-23 antagonist and a corticosteroid. The combination therapy of the present invention can be used to treat, prevent or alleviate plaque psoriasis. Supplementing IL-23 inhibitor therapy with a corticosteroid will enhance the anti-psoriatic therapeutic effect of the IL-23 inhibitor.
[0010] Accordingly, the present invention provides one or more of the following embodiments.
[0011] In one embodiment, the present invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis, the method comprising:
[0012] choose
[0013] PASI score ≥12
[0014] ≥10% of body surface area (BSA) affected by psoriasis and / or
[0015] Patients with a PGA score ≥3
[0016] administering an IL-23 inhibitor to the patient at a dose of about 100 mg by subcutaneous injection at weeks 0, 4, and 16;
[0017] At week 16, patients with BSA > 3% were given corticosteroids twice daily for 4 weeks and then followed up for an additional four weeks without the corticosteroids, and
[0018] Changes from baseline in BSA, PGA, PGAxBSA, PSAI, and DLQI were recorded; patients receiving the corticosteroids achieved BSA ≤1% to ≤3% at Week 20 and maintained response levels through Week 24.
[0019] In another embodiment, the invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis wherein the mean percent reductions from baseline in BSA, PGA, and PGA x BSA are significantly increased at week 20 after 4 weeks of adjunctive corticosteroid therapy and the response is maintained at week 24 after 4 weeks of cessation of corticosteroid therapy.
[0020] In yet another embodiment, the present invention provides a method for treating patients suffering from moderate to severe plaque psoriasis, wherein the percent reduction from baseline in PSAI (75, 90, and 100) at week 20 is significantly increased after 4 weeks of adjunctive corticosteroid therapy and the response is maintained at week 24 after cessation of corticosteroid therapy for 4 weeks.
[0021] In yet another embodiment, the invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis wherein the reduction in DLQI from baseline at week 20 is significantly increased after 4 weeks of adjunctive corticosteroid therapy and the response is maintained at week 24 after 4 weeks of cessation of corticosteroid therapy.
[0022] In still yet another embodiment, the invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis wherein the corticosteroid is administered as a topical formulation.
[0023] In one embodiment, the present invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis, wherein the topical formulation is in the form of an ointment, powder, gel ointment, emollient, cream, adhesive patch or strip, shampoo, spray, foam, gel, liquid or solution.
[0024] In another embodiment, the invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis, wherein the corticosteroid is administered as an ointment, preferably a 0.1% ointment.
[0025] In yet another embodiment, the present invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis, wherein the corticosteroid is selected from beclomethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, clobetasol propionate, clocortolone acetate, clocortolone pivalate, corticosterone, cortisone, desoximetasone acetate, fluocinolone acetate, halcinonide, halobetasol propionate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone probutyrate, hydrocortisone phosphate, hydrocortisone sodium succinate, methylprednisolone acetate, prednisolone or prednisone. In one embodiment, the corticosteroid is halcinonide. In another embodiment, the corticosteroid is prednisone.
[0026] In still another embodiment, the present invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis, wherein the IL-23 inhibitor is selected from guselkumab, risankizumab, or teikizumab.
[0027] In another embodiment, the invention provides a method for treating a patient suffering from moderate to severe plaque psoriasis, wherein the IL-23 antagonist is teikizumab.
[0028] In yet another embodiment, the invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, comprising continuing treatment with the IL-23 antagonist, initiating treatment with a topical formulation comprising a corticosteroid, continuing treatment with said topical formulation comprising said corticosteroid for no more than 4 weeks, and then discontinuing treatment with said topical formulation, wherein after only 4 weeks of supplemental corticosteroids are applied to those patients who have not achieved an adequate response to the IL-23 antagonist alone, the percentage of patients achieving a BSA ≤ 3% is increased, and said improvement is maintained 4 weeks after cessation of corticosteroid treatment.
[0029] In yet another embodiment, the invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the percent reductions from baseline in mean BSA, PGA, and PGA xBSA at week 20 after 4 weeks of adjunctive corticosteroid therapy are significantly increased; the percent reductions from baseline in PSAI (75, 90, and 100) at week 20 after 4 weeks of adjunctive corticosteroid therapy are significantly increased; the reduction from baseline in DLQI at week 20 after 4 weeks of adjunctive corticosteroid therapy is significantly increased; and the response (all outcomes) is maintained at week 24 after 4 weeks of cessation of corticosteroids.
[0030] In yet another embodiment, the invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the patient continues treatment with the IL-23 antagonist for at least about 16 weeks.
[0031] In yet another embodiment, the present invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the IL-23 antagonist is guselkumab, risenkizumab, or teikizumab.
[0032] In yet another embodiment, the invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the IL-23 antagonist is tirizimab.
[0033] In still another embodiment, the invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the corticosteroid is administered as a topical formulation.
[0034] In one embodiment, the invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the topical formulation is in the form of an ointment, powder, gel ointment, emollient, cream, adhesive patch or strip, shampoo, spray, foam, gel, liquid or solution.
[0035] In yet another embodiment, the present invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the corticosteroid is selected from beclomethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, clobetasol propionate, clocortolone acetate, clocortolone pivalate, corticosterone, cortisone, desoximetasone acetate, fluocinolone acetonide, halcinonide, halobetasol propionate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone probutyrate, hydrocortisone phosphate, hydrocortisone sodium succinate, methylprednisolone acetate, prednisolone, prednisone or halcinonide, preferably halcinonide.
[0036] In still yet another embodiment, the invention provides a method for treating a patient with psoriasis who is receiving an IL-23 antagonist, wherein the corticosteroid is halcinonide ointment, preferably 0.1% ointment. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1: Proportions of patients achieving BSA ≤ 3% and BSA ≤ 1% at Weeks 16, 20, and 24 among all patients (A) and among patients with BSA > 3% at Week 16 who received halcinonide (B).
[0038] Figure 2: Mean BSA involvement at different time points for all patients, patients with BSA ≤ 3% at Week 16, and patients with BSA > 3% at Week 16 (n represents the number of patients with available data at each study visit).
[0039] Figure 3 : Mean PGA scores at different time points for all patients, patients with BSA ≤ 3% at week 16, and patients with BSA > 3% at week 16 (n represents the number of patients with available data at each study visit).
[0040] Figure 4 : Mean PGA x BSA at different time points for all patients, patients with BSA ≤ 3% at Week 16, and patients with BSA > 3% at Week 16 (n represents the number of patients with available data at each study visit).
[0041] Figure 5 : Proportion of all patients achieving PASI 75, PASI 90, and PASI 100 responses at Weeks 16, 20, and 24.
[0042] Figure 6: Improvement in quality of life. (A) Proportion of patients achieving a DLQI of 0 or 1 and (B) mean DLQI at different time points for all patients, patients with BSA ≤ 3% at week 16, and patients with BSA > 3% at week 16 (n represents the number of patients with available data at each study visit).
[0043] The above aspects and embodiments as well as other aspects, objects, features and advantages of the present invention will become apparent from the following detailed description. DETAILED DESCRIPTION
[0044] In a cohort study, almost half of the patients did not achieve BSA 3% at week 16 using tiriguzumab. Therefore, there is a need to develop a new therapy involving adjuvant therapy or switch to a new therapy. In the present invention, after only 4 weeks of supplemental halcinonide ointment was applied to those patients who did not achieve an adequate response to tiriguzumab alone, the proportion of all patients who achieved BSA ≤ 3% and PASI 75 increased. All disease activity outcomes and patient quality of life were improved with tiriguzumab monotherapy and further supplementation with halcinonide ointment. Importantly, the improvement was maintained 4 weeks after cessation of halcinonide ointment. In addition, tiriguzumab alone or in combination with halcinonide ointment was well tolerated and no SAEs were found.
[0045] Thus, a method for treating patients suffering from moderate to severe plaque psoriasis is provided, comprising a) selecting patients with a PASI score ≥12; ≥10% of body surface area (BSA) affected by psoriasis and / or a PGA score ≥3; b) administering an IL-23 antagonist, preferably teixumab, to said patients at a dose of about 100 mg by subcutaneous injection at weeks 0, 4 and 16; c) applying halcinonide twice daily to patients with BSA>3% at week 16 for 4 weeks, and then continuing follow-up for another four weeks without halcinonide, and recording changes from baseline in BSA, PGA, PGAxBSA, PSAI and DLQI; wherein:
[0046] a. Patients receiving halcinonide achieved BSA ≤1% to ≤3% at week 20;
[0047] b. The mean BSA, PGA, and PGA x BSA percentage reductions from baseline at week 20 were significantly increased after 4 weeks of adjunctive halcinonide therapy;
[0048] c. The percent reduction from baseline in PSAI (75, 90, and 100) at week 20 after 4 weeks of adjunctive halcinonide therapy was significantly increased;
[0049] d. the reduction in DLQI from baseline at week 20 after 4 weeks of adjunctive halcinonide therapy was significantly greater; and
[0050] e. The response was maintained at week 24 after cessation of halcinonide ointment for 4 weeks.
[0051] In another embodiment, a method for treating a patient with psoriasis who is receiving an IL-23 antagonist is provided, comprising continuing treatment with the IL-23 antagonist, initiating treatment with a topical formulation comprising a corticosteroid, continuing treatment with the topical formulation comprising the corticosteroid for no more than 4 weeks, and then discontinuing treatment with the topical formulation, wherein after only 4 weeks of supplemental corticosteroids are applied to those patients who have not achieved an adequate response to the IL-23 antagonist alone, the percentage of patients achieving BSA ≤ 3% and PASI (75, 90, or 100) is increased, and the improvements are maintained 4 weeks after cessation of corticosteroid treatment.
[0052] Next, as used herein, unless otherwise expressly stated, the following definitions apply. For example, the term "IL-23 antagonist or inhibitor" targets a cytokine called IL-23, which plays a role in the signal transduction pathway that triggers inflammation. IL-23 inhibitors block the action of IL-23, which helps limit the inflammation that causes psoriasis symptoms. IL-23 inhibitors can help reduce the amount of skin affected by psoriasis and also relieve symptoms such as itching, pain, and skin tightness. The FDA has approved three IL-23 inhibitors for the treatment of moderate to severe psoriasis in adults. They are guselkumab (TREMFYA), liscentizumab-rzaa (SKYRIZI) and tirizizumab-asmn (ILUMYA).
[0053] Guselkumab, an interleukin-23 blocker, is a human immunoglobulin G1λ (IgG1λ) monoclonal antibody. Guselkumab is produced in a mammalian cell line using recombinant DNA technology. TREMFYA injection is a sterile, preservative-free, clear, colorless to light yellow solution that may contain small translucent particles. Each single-dose prefilled syringe for subcutaneous use contains 100 mg of guselkumab in 1 mL. TREMFYA is supplied as a single-dose solution in a 1 mL glass syringe with a 27G half-inch fixed needle assembled in a passive needle shield delivery system. The standard dose is one injection at the start of treatment, one injection during the fourth week of treatment, and every 8 weeks thereafter. Each TREMFYA prefilled syringe delivers 1 mL of a solution containing guselkumab (100 mg), histidine (0.6 mg), L-histidine monohydrochloride monohydrate (1.5 mg), polysorbate 80 (0.5 mg), sucrose (79 mg), and water for injection at pH 5.8.
[0054] In another embodiment, a method for treating a patient with psoriasis who is receiving guselkumab is provided, comprising continuing treatment with guselkumab, initiating treatment with a topical formulation containing a corticosteroid, continuing treatment with the topical formulation containing the corticosteroid for no more than 4 weeks, and then discontinuing treatment with the topical formulation, wherein the percentage of patients achieving BSA ≤ 3% and PASI (75, 90, or 100) is increased after only 4 weeks of supplemental corticosteroids are applied to those patients who did not achieve an adequate response to guselkumab alone, and the improvements are maintained 4 weeks after cessation of corticosteroid treatment.
[0055] Risenqizumab-rzaa, an interleukin-23 antagonist, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Risenqizumab-rzaa is produced in a mammalian cell line using recombinant DNA technology. SKYRIZI (Risenqizumab-rzaa) injection is a sterile, preservative-free, colorless to slightly yellowish, clear to slightly opalescent solution for subcutaneous use. Each prefilled syringe delivers 0.83 mL of solution, which contains 75 mg of Risenqizumab-rzaa, disodium succinate hexahydrate (0.88 mg), polysorbate 20 (0.17 mg), sorbitol (34 mg), succinic acid (0.049 mg), and water for injection USP.
[0056] In yet another embodiment, a method for treating a patient with psoriasis who is receiving risankizumab is provided, comprising continuing treatment with risankizumab, initiating treatment with a topical formulation containing a corticosteroid, continuing treatment with the topical formulation containing the corticosteroid for no more than 4 weeks, and then discontinuing treatment with the topical formulation, wherein after only 4 weeks of supplemental corticosteroids are applied to those patients who do not achieve an adequate response to risankizumab alone, the percentage of patients achieving BSA ≤ 3% and PASI (75, 90, or 100) is increased, and the improvements are maintained 4 weeks after cessation of corticosteroid treatment.
[0057] Tirekizumab-ASMN is a humanized IgG1 / kappa antibody that specifically binds to the p19 subunit of interleukin-23 (IL-23). Tirekizumab-ASMN is produced in a recombinant Chinese hamster ovary (CHO) cell line and has an approximate molecular weight of 147 kilodaltons. ILUMYA (tirekizumab-ASMN) injection, for subcutaneous use, is a sterile, clear to slightly opalescent, colorless to slightly yellowish solution. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and a 29-gauge fixed 1 / 2-inch needle. The syringe is equipped with a passive needle shield and needle cover. Each 1 mL single-dose prefilled syringe contains 100 mg of teikizumab-asmn formulated in: histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection USP, pH 5.7-6.3.
[0058] In a specific embodiment, the present invention provides a method for treating a patient with psoriasis who is receiving teikizumab, comprising continuing treatment with teikizumab, initiating treatment with a topical formulation containing a corticosteroid, continuing treatment with the topical formulation containing the corticosteroid for no more than 4 weeks, and then discontinuing treatment with the topical formulation, wherein after only 4 weeks of supplemental corticosteroids are applied to those patients who did not achieve an adequate response to teikizumab alone, the percentage of patients achieving BSA ≤ 3% and PASI (75, 90, or 100) is increased, and the improvements are maintained 4 weeks after cessation of corticosteroid treatment.
[0059] The term "corticosteroid" refers to a group of hormones and their analogs secreted by the adrenal cortex. "Corticosteroid" covers glucocorticoids, mineralocorticoids (such as aldosterone) and sex steroids. Glucocorticoids such as cortisol bind to glucocorticoid receptors, have anti-inflammatory, metabolic and immunomodulatory effects and regulate key homeostatic functions. Some corticosteroids, such as cortisone, have both glucocorticoid and mineralocorticoid effects, while others mainly have glucocorticoid effects.
[0060] A "topical preparation containing a corticosteroid" may be in the form of an ointment, powder, gel ointment, emollient, cream, adhesive patch or strip, shampoo, spray, foam, gel or liquid.
[0061] Examples of corticosteroids include, but are not limited to, beclomethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, clobetasol propionate, clocortolone acetate, clocortolone pivalate, corticosterone, cortisone, desoximetasone acetate, fluocinolone acetonide, halcinonide, halobetasol propionate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone propionate, hydrocortisone phosphate, hydrocortisone sodium succinate, methylprednisolone acetate (or disodium phosphate, sodium succinate or aceponate), prednisolone, halcinonide, prednisone, and the like.
[0062] As used herein, the term "halcinonide" refers to HALOG, whose chemical name is 21-chloro-9-fluoro-11β,16α,17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-propanone acetal. Each gram of 0.1% HALOG (halcinonide cream, USP) contains 1 mg of halcinonide in a specially formulated cream base consisting of cetyl alcohol, dimethicone 350, glyceryl monostearate NF XII, isopropyl palmitate, polysorbate 60, propylene glycol, purified water, and titanium dioxide.
[0063] Each mL of 0.1% HALOG solution (halcinonide topical solution, USP) contains 1 mg of halcinonide, edetate disodium, polyethylene glycol 300, and purified water with butylated hydroxytoluene as an antioxidant.
[0064] 0.1% HALOG Ointment (Halcinonide Ointment, USP) per gram (plasticized hydrocarbon gel), mineral oil and polyethylene gel base, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 1450 and polyethylene glycol 6000 distearate containing 1 mg of halcinonide and butylated hydroxytoluene as an antioxidant.
[0065] As used herein, the term "about" refers to any value within a range defined by a variation of up to ±15% of the value.
[0066] The present invention is described below by reference to the following examples. However, it will be appreciated by those skilled in the art that the specific methods and results discussed are merely illustrative of the present invention, because numerous variations, modifications, applications and extensions may be made to these embodiments and principles without departing from the spirit and scope of the present invention.
[0067] Example 1
[0068] A prospective, open-label study evaluating the efficacy and safety of tirizimab plus topical halcinonide ointment in patients with psoriasis
[0069] method
[0070] Study Design and Participants
[0071] This is a single-center, prospective, open-label study to evaluate the efficacy of tiricizumab ( [Tirekizumab-asmn) and halcinonide ointment ( The efficacy and safety of halcinonide ointment [halcinonide ointment, USP, 0.1%) in combination with sedative for the treatment of moderate to severe plaque psoriasis. The study protocol was approved by the institutional review committee and the study was conducted in accordance with ethical guidelines. Written informed consent was obtained from all patients before starting treatment.
[0072] Adults (≥18 years) with chronic, moderate-to-severe plaque psoriasis (BSA ≥10%, Physician Global Assessment [PGA] ≥3, Psoriasis Area Severity Index [PASI] ≥12) who were candidates for phototherapy and / or systemic therapy were enrolled. Exclusion criteria included active nonplaque forms of psoriasis; laboratory abnormalities or medical conditions that could affect patient safety during the study; active or untreated latent tuberculosis; previous or concurrent malignancy; hepatitis B; recent use of UVB or PUVA phototherapy, oral systemic medications, biologics, or topical therapies for psoriasis; recent use of antibiotics or any study medication; pregnancy or breastfeeding; and hypersensitivity to excipients of the study medication. Patients who had received a live vaccine within 4 weeks before baseline or intended to receive a live vaccine during the study were also excluded.
[0073] Study Treatment
[0074] All enrolled patients received teikizumab (100 mg) by subcutaneous injection at Weeks 0, 4, and 16. Patients with BSA>3% at Week 16 applied halcinonide ointment twice daily for 4 weeks and then continued follow-up for another 4 weeks without halcinonide. Patients with BSA≤3% at Week 16 were also followed up to Week 24. Safety and efficacy were evaluated for all patients at Weeks 4, 8, 16, 20, and 24.
[0075] Study Results
[0076] The primary endpoint of the study was the proportion of patients with BSA ≤ 3% at Week 16. Secondary endpoints included the proportion of patients with BSA ≤ 1%, Dermatology Life Quality Index (DLQI) of 0 or 1, and a 75%, 90%, and 100% reduction in PASI score from baseline (PASI 75, PASI 90, and PASI 100, respectively) at Weeks 16, 20, and 24, and the proportion of patients with BSA ≤ 3% at Weeks 20 and 24. Improvement in PGA, the composite PGA x BSA metric, and DLQI were also evaluated as secondary endpoints. Safety outcomes included adverse events (AEs) and serious AEs (SAEs).
[0077] Statistical analysis
[0078] A cohort of approximately 25 participants was planned to be enrolled in the study. Changes from baseline in BSA, PGA, PGA x BSA, PASI, and DLQI at Weeks 4, 8, 16, 20, and 24 were summarized descriptively; no formal statistical analysis was performed given the sample size. AEs and SAEs were summarized descriptively by frequency and severity, and their causal relationship to treatment was assessed.
[0079] result
[0080] Patient Disposition and Demographics
[0081] A total of 25 patients were enrolled, of whom 19 completed the study; 1 discontinued the study due to non-response to treatment, and 5 were lost to follow-up.
[0082] Most patients were male (68%) and white (76%), with a mean age of 52.6 years. Patients had psoriasis for a mean of 18.9 years. The mean baseline BSA was 19.1%, and the mean baseline PGA score was 3.5, PASI score was 16.7, and DLQI score was 16.5. At week 16, 12 patients had a BSA ≤ 3%, while 11 patients had a BSA > 3% and continued to receive supplemental halcinonide ointment for 4 weeks.
[0083] BSA and PGA reactions
[0084] With tiriguzumab, the proportion of all patients achieving BSA ≤ 3% at Week 16 was 52.2%. At Week 20 (after 4 weeks of supplemental halcinonide ointment for patients with unsatisfactory Week 16 responses), this percentage increased to 73.7% for all patients (≤ 3% and > 3% BSA at Week 16) and reached 84.2% at Week 24 after patients had not used halcinonide ointment for 4 weeks (Figure 1A). Of the patients who supplemented with halcinonide therapy at Week 16, 4 achieved BSA ≤ 3% at Week 20 and maintained the response level through Week 24, 1 achieved BSA ≤ 3% at Week 20 but lost the response at Week 24 (BSA 6%), and 1 achieved BSA ≤ 3% at Week 24, resulting in a total of 62.5% of this group achieving BSA ≤ 3% at the end of the study (Figure 1B). Most patients who completed the study with BSA ≤ 3% at week 16 (without halcinonide) maintained BSA ≤ 3% at weeks 20 and 24; one patient's BSA increased to 4% at week 20 but fell back to 3% at week 24. The proportion of all patients with BSA ≤ 1% also increased from 21.7% at week 16 to 42.1% at week 20 and 36.8% at week 24 (Figure 1A). Among patients taking halcinonide, 22.2% achieved BSA ≤ 1% at week 20 and 12.5% at week 24 (Figure 1B).
[0085] The mean BSA involvement of all patients decreased from 19.1% at baseline to 5.0% at week 16 (a 74% reduction), 2.6% at week 20, and 2.7% at week 24 (all 86% reductions) ( Figure 2). Mean PGA and PGA x BSA for all patients also improved with treatment. In patients with BSA > 3% at Week 16, the mean BSA, PGA, and PGA x BSA reductions from baseline were 55%, 29%, and 64%, respectively, at Week 16 and 78%, 51%, and 88%, respectively, at Week 20 after 4 weeks of adjunctive halcinonide therapy; these responses were maintained at Week 24 after 4 weeks of discontinuation of halcinonide ointment. In patients with BSA ≤ 3% at Week 16 who did not use halcinonide, the mean BSA, PGA, and PGA x BSA scores decreased by 89%, 60%, and 95%, respectively, from baseline to Week 16, and the responses were maintained through Week 24 ( Figure 2-4 ).
[0086] PASI response
[0087] At Week 16, 60.9% of all patients achieved PASI 75 (≥75% reduction in PASI score from baseline) in response to teikizumab monotherapy, a percentage that increased to 73.7% at Weeks 20 and 24. The percentage of all patients achieving PASI 90 also increased from 17.4% at Week 16 to 52.6% at Week 24. PASI 100 (complete resolution) was achieved by 4.3% of all patients at Week 16 and 21.1% of all patients at Week 20, but fell to 5.3% (95% CI, 2.3% to 2.1%) 4 weeks after stopping halcinonide therapy. Figure 5 ).
[0088] Quality of Life
[0089] After 16 weeks of tiriguzumab monotherapy, the proportion of all patients reporting a DLQI score of 0 or 1 increased from 4.0% at baseline to 39.2% at week 16 and continued to increase at week 20 (42.1%) but decreased to 31.6% at week 24 (Figure 6A).
[0090] The mean DLQI for all patients decreased by 68% from baseline to week 16, and this improvement was maintained through week 24. In patients with BSA > 3% who used supplemental halcinonide ointment, the reduction in mean DLQI from baseline increased from 50% at week 16 to 65% at week 20 and 61% at week 24. In patients with BSA ≤ 3% at week 16 who did not use halcinonide ointment, the mean DLQI improved by 84% from baseline to week 16 and remained at similar levels at weeks 20 and 24 (Figure 6B).
Claims
1. A method for treating a patient suffering from moderate to severe plaque psoriasis, the method comprising: choose PASI score ≥12 ≥10% of body surface area (BSA) affected by psoriasis and / or Patients with a PGA score ≥ 3 administering an IL-23 inhibitor to the patient at a dose of about 100 mg by subcutaneous injection at weeks 0, 4, and 16; At week 16, patients with BSA > 3% were given corticosteroids twice daily for 4 weeks and then followed up for an additional four weeks without the corticosteroids, and Changes from baseline in BSA, PGA, PGAxBSA, PSAI, and DLQI were recorded; patients receiving the corticosteroids achieved BSA ≤1% to ≤3% at Week 20 and maintained response levels through Week 24.
2. The method of claim 1, wherein the mean BSA, PGA, and percent reduction from baseline in PGA x BSA are significantly increased at week 20 after 4 weeks of adjunctive corticosteroid therapy and the response is maintained at week 24 after 4 weeks of cessation of corticosteroid therapy.
3. The method of claim 1, wherein the percent reduction in PSAI (75, 90, and 100) relative to baseline is significantly increased at week 20 after 4 weeks of adjunctive corticosteroid therapy and the response is maintained at week 24 after 4 weeks of cessation of corticosteroid therapy.
4. The method of claim 1, wherein the reduction in DLQI from baseline at week 20 is significantly increased after 4 weeks of adjunctive corticosteroid therapy and the response is maintained at week 24 after 4 weeks of cessation of corticosteroid therapy.
5. The method of claim 1, wherein the corticosteroid is administered as a topical formulation.
6. The method of claim 5, wherein the topical formulation is in the form of an ointment, powder, gel ointment, emollient, cream, adhesive patch or strip, shampoo, spray, foam, gel, liquid or solution.
7. The method of claim 5, wherein the corticosteroid is administered as an ointment.
8. The method according to any one of claims 1 to 7, wherein the corticosteroid is selected from beclomethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, clobetasol propionate, clocortolone acetate, clocortolone pivalate, corticosterone, cortisone, desoximetasone acetate, fluocinolone acetonide, halcinonide, halobetasol propionate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone probutyrate, hydrocortisone phosphate, hydrocortisone sodium succinate, methylprednisolone acetate, prednisolone or prednisone.
9. The method of claim 1, wherein the IL-23 inhibitor is selected from guselkumab, risenkizumab, or teikizumab.
10. The method of claim 1, wherein the IL-23 antagonist is teikizumab.
11. A method for treating a patient with psoriasis who is receiving an IL-23 antagonist, the method comprising continuing treatment with the IL-23 antagonist, initiating treatment with a topical formulation comprising a corticosteroid, continuing treatment with the topical formulation comprising the corticosteroid for no more than 4 weeks, and then discontinuing treatment with the topical formulation, wherein after applying only 4 weeks of supplemental corticosteroids to those patients who have not achieved an adequate response to the IL-23 antagonist alone, the percentage of patients achieving a BSA ≤ 3% is increased, and the improvement is maintained 4 weeks after cessation of corticosteroid treatment.
12. The method of claim 11, wherein the percent reductions from baseline in mean BSA, PGA, and PGA x BSA at week 20 are significantly increased after 4 weeks of adjunctive corticosteroid therapy; the percent reductions from baseline in PSAI (75, 90, and 100) at week 20 are significantly increased after 4 weeks of adjunctive corticosteroid therapy; the reductions from baseline in DLQI at week 20 are significantly increased after 4 weeks of adjunctive corticosteroid therapy; and the response is maintained at week 24 after cessation of corticosteroid therapy for 4 weeks.
13. The method of claim 11, wherein the patient continues treatment with the IL-23 antagonist for at least about 16 weeks.
14. The method of claim 11, wherein the IL-23 antagonist is guselkumab, risenkizumab, or teikizumab.
15. The method of claim 11, wherein the IL-23 antagonist is tislekizumab.
16. The method of claim 11, wherein the corticosteroid is administered as a topical formulation.
17. The method of claim 16, wherein the topical formulation is in the form of an ointment, powder, gel ointment, emollient, cream, adhesive patch or strip, shampoo, spray, foam, gel, liquid or solution.
18. The method of claim 11, wherein the corticosteroid is selected from beclomethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, clobetasol propionate, clocortolone acetate, clocortolone pivalate, corticosterone, cortisone, desoximetasone acetate, fluocinolone acetonide, halcinonide, halobetasol propionate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone probutyrate, hydrocortisone phosphate, hydrocortisone sodium succinate, methylprednisolone acetate, prednisolone, prednisone or halcinonide.
19. The method of any one of claims 16 to 18, wherein the corticosteroid is halcinonide ointment.
